2Sarkissian T, Beyenne J, Feldman B , et al. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus[ J]. Arthrities Rheum,2006,54 (4) : 1283 - 1290.
3Ettinger WH, Goldberg AP, Applebaum Bowden D, et al. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids[ J]. Am J Med,1987,83(3) :503 -508.
4Svens0n KL, Lundqvist G, Wide L, et al. Impaired glucose handling in active rheumatoid arthritis, effects of corticosteroids and antirheumatic treatment [J ]. Metabolism, 1987,36 ( 10 ) - 944 - 948.
5Petri M. Detection of coronary artery disease and the role of tradi- tional risk factors in the Hopkins Lupus Cohort [ J ] Lupus,2000,9 (3) :170 - 175.
6Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis[ J]. Thromb J ,2015,13 : 16.
7Skaggs B J, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE - mechanisms and management [ J ]. Nat Rev Rheumatol,2012,8 (4) : 214 - 223.
8Pego - Reigosa JM, Rua - Figueroa l, Lopez - Longo FJ, et al. Analysis ,of disease activity and response to treatment in a largeSpanish cohort of patients with systemic lupus erythematosus[ J ]. Lupus,2015,24 (7) :720 - 729.
9Sinieato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus [ J ]. Curr Cardiol Rev,2013,9( 1 ) :15 -19.
10PanaroUn D, Remillard P, Rouffard L, et al. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue speeitfic manner [J]. Eur J Clin Invest, 2002,32(2) :84 -92.
